MindMaze Group Secures USD 125 Million Financing

Financing to Accelerate Commercialization and Expansion of its Digital Neurotherapeutics Platform

MindMaze, a global pioneer in the multibillion-dollar digital neurotherapeutics market, today announced the closing of a USD 125 million investment round that will be utilized to drive the continued growth of its SaaS-based digital neurotherapeutics platform. The financing was provided by AlbaCore Capital Group, one of Europe’s leading specialist investors focusing on public and private corporate credit markets.

MindMaze will use the proceeds to accelerate commercialization of, and enhance market access for, its approved and reimbursed neuro-rehabilitation platform, particularly in North America and Europe, and expand its neuro-restorative  portfolio through further system development and clinical trials in additional indications including acute stroke, Parkinson disease, Alzheimer disease, traumatic brain injury, multiple sclerosis and aging. The investment in MindMaze represents one of the top-three private capital raises in the Continental European digital health space and will serve to bolster one of the premier European HealthTech leaders.

MindMaze is the global leader in digital neurotherapeutics, delivering seamless digital assessments and therapeutics over the full continuum of care in over twenty countries, with thousands of patients suffering from neurological conditions. The Company currently collaborates with approximately ninety healthcare providers and has a product portfolio that has received three FDA clearances and four CE marks across eight clinical indications. Backed by over seventy patent families, MindMaze’s innovative digital neurotherapeutics platform combines highly engaging, personalized, protocolized, quantified, gamified digital therapeutic content supported by tailored smart peripherals that target two distinct areas of care: neuro-rehabilitation and neuro-restoration. MindMaze is partnering with leading academic and medical institutions, including Johns Hopkins University School of Medicine, the Mount Sinai Health System and the University of California San Francisco (UCSF) in the United States, the Lausanne University Hospital (CHUV) and the Swiss Federal Institution of Technology (EPFL) in Switzerland, and the Institute for the Brain and Spinal Cord (ICM) in France, to further develop and demonstrate the efficacy of its market leading solution set.

“MindMaze is dedicated to improving the lives of patients around the world through the development of novel digital therapeutic products for the treatment of serious neurological conditions. We have built the leading neuro-focused digital health platform comprehensively addressing full body motor and cognitive challenges associated with key neurological conditions.  We believe that the demands of a rapidly aging world population make our proprietary, proven solutions more critical now than ever before,” stated Tej Tadi, PhD, MindMaze founder and CEO. “This investment by AlbaCore will allow us to accelerate our proven neuro-rehab platform and advance commercialization of our evidence-based neuro-restorative solutions in stroke, traumatic brain, aging and Parkinson disease. One avenue to pursue will be to partner with pharmaceutical companies to promote brain repair by combining our digital therapeutic neurorestorative approach with emerging drug discovery. We are thrilled to partner with AlbaCore as we build the leading universal platform for brain health and recovery. This financing will enable our dedicated team and partners to advance in our mission to help patients recover, learn and adapt through advanced neuroscience and digital therapeutics.”

AlbaCore Capital Group’s Managing Partner and Chief Investment Officer, David Allen, says: “We are excited to partner with MindMaze and empower their critically important mission to change the face of brain health and recovery through advanced digital tools. At AlbaCore, we look to be a creative solutions provider with partnership at the core of everything we do. We believe that MindMaze is positioned to dramatically improve care for millions of patients, and with this fresh capital will be able to rapidly scale.”

SourceMindMaze
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy